Trial Outcomes & Findings for Memantine Augmentation of Targeted Cognitive Training in Schizophrenia (NCT NCT04857983)
NCT ID: NCT04857983
Last Updated: 2026-05-18
Results Overview
PANSS Total Score is the primary clinical outcome measured at baseline vs. post TCT session 10, 20 and 30 (approximately 16 weeks). The PANSS total score has a range 30-210, with higher scores indicating worse outcome.
COMPLETED
PHASE2/PHASE3
62 participants
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
2026-05-18
Participant Flow
Antipsychotic-medicated outpatients with a primary diagnosis of SZ or schizoaffective disorder (depressed type) ages 18-65 were recruited from the San Diego community between 7/6/2021 and 11/15/2023. Of the 62 consented/enrolled participants, 42 met inclusion criteria and were randomized to treatment, however 2 dropped out prior to initiation of treatment. Therefore 40 subjects participated in the trial.
A total of 62 participants were enrolled but 15 were excluded for not meeting inclusion criteria and 5 withdrew from the study. Two withdrew before initiation of treatment; therefore 40 participants were included. 17 were randomized to placebo and 23 were randomized to memantine.
Participant milestones
| Measure |
TCT + PBO
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Overall Study
STARTED
|
17
|
23
|
|
Overall Study
COMPLETED
|
15
|
21
|
|
Overall Study
NOT COMPLETED
|
2
|
2
|
Reasons for withdrawal
| Measure |
TCT + PBO
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
2
|
|
Overall Study
Positive toxicology screen
|
1
|
0
|
Baseline Characteristics
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Baseline characteristics by cohort
| Measure |
TCT + PBO
n=17 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=23 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
Total
n=40 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=11 Participants
|
2 Participants
n=9 Participants
|
2 Participants
n=20 Participants
|
|
Age, Continuous
|
48.3 years
STANDARD_DEVIATION 12.07 • n=11 Participants
|
48.7 years
STANDARD_DEVIATION 12.8 • n=9 Participants
|
48.5 years
STANDARD_DEVIATION 12.34 • n=20 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=11 Participants
|
8 Participants
n=9 Participants
|
16 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
9 Participants
n=11 Participants
|
15 Participants
n=9 Participants
|
24 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=11 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=11 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=11 Participants
|
6 Participants
n=9 Participants
|
9 Participants
n=20 Participants
|
|
Race (NIH/OMB)
White
|
13 Participants
n=11 Participants
|
13 Participants
n=9 Participants
|
26 Participants
n=20 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=11 Participants
|
2 Participants
n=9 Participants
|
3 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=11 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=20 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=11 Participants
|
2 Participants
n=9 Participants
|
8 Participants
n=20 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
11 Participants
n=11 Participants
|
21 Participants
n=9 Participants
|
32 Participants
n=20 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=11 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=20 Participants
|
|
Region of Enrollment
United States
|
17 Participants
n=11 Participants
|
23 Participants
n=9 Participants
|
40 Participants
n=20 Participants
|
|
Duration of illness
|
20.7 years
STANDARD_DEVIATION 11.8 • n=11 Participants
|
26.8 years
STANDARD_DEVIATION 13.03 • n=9 Participants
|
24.25 years
STANDARD_DEVIATION 12.74 • n=20 Participants
|
PRIMARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
PANSS Total Score is the primary clinical outcome measured at baseline vs. post TCT session 10, 20 and 30 (approximately 16 weeks). The PANSS total score has a range 30-210, with higher scores indicating worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Positive & Negative Symptom Scale Total (PANSSt)
Post-10
|
52.23 score on a scale
Standard Deviation 9.74
|
49.29 score on a scale
Standard Deviation 12.80
|
|
Positive & Negative Symptom Scale Total (PANSSt)
Post-20
|
53.00 score on a scale
Standard Deviation 12.39
|
48.47 score on a scale
Standard Deviation 13.61
|
|
Positive & Negative Symptom Scale Total (PANSSt)
Post-30
|
51.54 score on a scale
Standard Deviation 11.08
|
46.12 score on a scale
Standard Deviation 12.30
|
|
Positive & Negative Symptom Scale Total (PANSSt)
Baseline
|
56.77 score on a scale
Standard Deviation 14.50
|
54.24 score on a scale
Standard Deviation 13.13
|
PRIMARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
Function will be assessed via the World Health Organization Disability Schedule 2.0 (WHODAS 2.0) at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The World Health Organization Disability Schedule (WHODAS 2.0) has a range 12-60, with higher scores indicating worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
World Health Organization Disability Schedule (WHODAS 2.0)
Baseline
|
20.31 score on a scale
Standard Deviation 8.93
|
23.06 score on a scale
Standard Deviation 8.81
|
|
World Health Organization Disability Schedule (WHODAS 2.0)
Post-10
|
21.62 score on a scale
Standard Deviation 8.10
|
24.94 score on a scale
Standard Deviation 10.09
|
|
World Health Organization Disability Schedule (WHODAS 2.0)
Post-20
|
18.77 score on a scale
Standard Deviation 7.60
|
23.65 score on a scale
Standard Deviation 10.53
|
|
World Health Organization Disability Schedule (WHODAS 2.0)
Post-30
|
20.38 score on a scale
Standard Deviation 8.44
|
23.12 score on a scale
Standard Deviation 9.58
|
PRIMARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
The MCCB Global Composite T-score (MCCB-C) is the primary neurocognitive outcome measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The MATRICS Consensus Cognitive Battery (MCCB) composite T-score has no minimum or maximum score because it uses T-scores (e.g., 50 indicates the population mean with a standard deviation of 10), which are standardized based on a community sample. A normal range MCCB composite T-score is between 40 and 60 and higher scores indicate better neurocognitive outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C)
Baseline
|
36.38 T-score
Standard Deviation 12.49
|
31.00 T-score
Standard Deviation 13.88
|
|
MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C)
Post-10
|
38.46 T-score
Standard Deviation 10.72
|
33.76 T-score
Standard Deviation 15.54
|
|
MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C)
Post-20
|
42.23 T-score
Standard Deviation 13.35
|
36.29 T-score
Standard Deviation 14.70
|
|
MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C)
Post-30
|
40.69 T-score
Standard Deviation 14.68
|
36.47 T-score
Standard Deviation 15.99
|
SECONDARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
Positive \& Negative Symptom Scale (PANSS) positive symptom subscale measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The PANSS positive symptom subscale is rated from 1 to 7 points ranging from absent to extreme. The range for the Positive Symptom subscale is 7-49 and higher scores indicate worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Positive & Negative Symptom Scale (PANSS) - Positive Symptom Subscale
Post-10
|
14.31 score on a scale
Standard Deviation 2.95
|
11.29 score on a scale
Standard Deviation 3.80
|
|
Positive & Negative Symptom Scale (PANSS) - Positive Symptom Subscale
Post-20
|
14.15 score on a scale
Standard Deviation 4.00
|
12.18 score on a scale
Standard Deviation 4.00
|
|
Positive & Negative Symptom Scale (PANSS) - Positive Symptom Subscale
Post-30
|
13.54 score on a scale
Standard Deviation 3.64
|
11.65 score on a scale
Standard Deviation 4.14
|
|
Positive & Negative Symptom Scale (PANSS) - Positive Symptom Subscale
Baseline
|
14.08 score on a scale
Standard Deviation 3.42
|
13.41 score on a scale
Standard Deviation 4.61
|
SECONDARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
Positive \& Negative Symptom Scale (PANSS) negative symptom subscale measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The PANSS negative symptom subscale is rated from 1 to 7 points ranging from absent to extreme. The range for the negative symptom subscale is 7-49 and higher scores indicate worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Positive & Negative Symptom Scale (PANSS) - Negative Symptom Subscale
Baseline
|
13.62 score on a scale
Standard Deviation 5.41
|
13.65 score on a scale
Standard Deviation 5.23
|
|
Positive & Negative Symptom Scale (PANSS) - Negative Symptom Subscale
Post-10
|
12.07 score on a scale
Standard Deviation 3.23
|
12.76 score on a scale
Standard Deviation 3.77
|
|
Positive & Negative Symptom Scale (PANSS) - Negative Symptom Subscale
Post-20
|
12.08 score on a scale
Standard Deviation 4.13
|
11.82 score on a scale
Standard Deviation 4.61
|
|
Positive & Negative Symptom Scale (PANSS) - Negative Symptom Subscale
Post-30
|
11.61 score on a scale
Standard Deviation 3.50
|
10.76 score on a scale
Standard Deviation 3.05
|
SECONDARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
Psychotic Symptom Rating Scales (PSYRATS hallucination subscale) measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The PSYRATS auditory hallucinations subscale (AHS) consisting of 11 items, with each item being rated from 0 (absent) to 4 (severe), range 0-44, with higher scores indicating more severe auditory hallucinations or worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Psychotic Symptoms - PSYRATS Hallucination Subscale
Baseline
|
12.62 score on a scale
Standard Deviation 12.90
|
7.35 score on a scale
Standard Deviation 9.20
|
|
Psychotic Symptoms - PSYRATS Hallucination Subscale
Post-10
|
14.92 score on a scale
Standard Deviation 12.89
|
6.24 score on a scale
Standard Deviation 9.43
|
|
Psychotic Symptoms - PSYRATS Hallucination Subscale
Post-20
|
13.23 score on a scale
Standard Deviation 12.17
|
7.18 score on a scale
Standard Deviation 12.83
|
|
Psychotic Symptoms - PSYRATS Hallucination Subscale
Post-30
|
15.38 score on a scale
Standard Deviation 11.97
|
7.65 score on a scale
Standard Deviation 10.61
|
SECONDARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
Young Mania Rating Scale total score measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The range for the YMRS total score is 0-60, with higher scores indicating more severe manic symptoms or worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Manic Symptoms - Young Mania Rating Scale
Post-20
|
4.62 score on a scale
Standard Deviation 4.52
|
2.65 score on a scale
Standard Deviation 4.66
|
|
Manic Symptoms - Young Mania Rating Scale
Post-30
|
3.31 score on a scale
Standard Deviation 3.54
|
2.41 score on a scale
Standard Deviation 4.02
|
|
Manic Symptoms - Young Mania Rating Scale
Baseline
|
3.38 score on a scale
Standard Deviation 3.15
|
2.53 score on a scale
Standard Deviation 3.68
|
|
Manic Symptoms - Young Mania Rating Scale
Post-10
|
3.54 score on a scale
Standard Deviation 4.16
|
2.53 score on a scale
Standard Deviation 3.41
|
SECONDARY outcome
Timeframe: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).Population: 17 subjects were randomized to placebo and 23 to memantine. 3 subjects withdrew and 1 was excluded for a positive toxicology test; therefore 15 placebo and 21 memantine subjects completed the post-10 assessment. 1 placebo and 3 memantine subjects withdrew prior to the post-20 assessment. One additional memantine subject withdrew so that 13 placebo and 17 memantine subjects completed the post-30 assessment. Data tables include only those subjects who completed all assessments through post-30.
Patient Health Questionnaire-9 (PHQ-9) total score measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks). The PHQ-9 has a range from 0 to 27 with higher scores indicating more severe depression or worse outcome.
Outcome measures
| Measure |
TCT + PBO
n=13 Participants
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + MEM
n=17 Participants
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Current Depressive Symptoms - PHQ-9
Baseline
|
6.85 score on a scale
Standard Deviation 4.38
|
8.18 score on a scale
Standard Deviation 7.36
|
|
Current Depressive Symptoms - PHQ-9
Post-20
|
6.62 score on a scale
Standard Deviation 5.64
|
6.65 score on a scale
Standard Deviation 7.11
|
|
Current Depressive Symptoms - PHQ-9
Post-30
|
6.69 score on a scale
Standard Deviation 6.47
|
5.76 score on a scale
Standard Deviation 5.60
|
|
Current Depressive Symptoms - PHQ-9
Post-10
|
5.69 score on a scale
Standard Deviation 3.30
|
6.29 score on a scale
Standard Deviation 6.80
|
Adverse Events
TCT + MEM
TCT + PBO
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
TCT + MEM
n=23 participants at risk
Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
TCT + PBO
n=17 participants at risk
Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
|
|---|---|---|
|
Psychiatric disorders
Positive CSSRS
|
17.4%
4/23 • From randomization until end of follow-up, up to 13 weeks
|
29.4%
5/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Psychiatric disorders
Positive tox
|
8.7%
2/23 • From randomization until end of follow-up, up to 13 weeks
|
41.2%
7/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Cardiac disorders
High BP
|
4.3%
1/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Psychiatric disorders
Worsening symptoms
|
4.3%
1/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Gastrointestinal disorders
GI Symptoms
|
8.7%
2/23 • From randomization until end of follow-up, up to 13 weeks
|
0.00%
0/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/23 • From randomization until end of follow-up, up to 13 weeks
|
11.8%
2/17 • From randomization until end of follow-up, up to 13 weeks
|
|
General disorders
Trip/fall
|
4.3%
1/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Infections and infestations
Positive COVID
|
0.00%
0/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Infections and infestations
Knee infection
|
0.00%
0/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Immune system disorders
Gout
|
0.00%
0/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
|
Infections and infestations
UTI Symptoms
|
0.00%
0/23 • From randomization until end of follow-up, up to 13 weeks
|
5.9%
1/17 • From randomization until end of follow-up, up to 13 weeks
|
Additional Information
Gregory A. Light, Ph.D.
University of California San Diego, Department of Psychiatry
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place